It was a pleasure to speak to Thomas Powles about his plenery session on the phase III interim analysis of the JAVELIN Bladder 100 study on maintenance avelumab and best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma.
1. What have we learned so far from clinical trials of immune checkpoint inhibition for urothelial cancer? (0:06)
2. What have been the latest efficacy and safety findings of the JAVELIN Bladder 100 trial? (0:32)
3. How do the findings of this study compare with those of other immune checkpoint inhibitors in this treatment setting? (1:54)
4. How can we predict which patients are most likely to respond to avelumab? (2:57)
5. What lies ahead in the treatment of urothelial cancer? (4:42)
Speaker disclosure: Thomas Powles has received honoraria from AstraZeneca, Bristol-Myers Squibb, Ferring, GLG Group, Janssen Research & Development, MERCK, Novartis, Pfizer, Roche/Genentech and Seattle Genetics/Astellas. He has held a consulting or advisory role for AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Incyte, Ipsen, Merck, Novartis, Pfizer and Seattle Genetics. He has received research funding from AstraZeneca/MedImmune and Roche/Genentech and travel, accommodations and expenses from AstraZeneca, Bristol-Myers Squibb, Ferring, MSD, Novartis/Ipsen, Pfizer, Research to Practice and Roche/Genentech.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2020 ASCO Virtual Scientific Program.
Share this Video
Related Videos In Bladder Cancer
Sebastian Schmid, ESMO 2022: RACE-IT – RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer
Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy following radical cystectomy in patients with locally […]
Robert Jones, ASCO 2022: Maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma – Phase 2 ATLANTIS trial
Cabozantinib is a targeted therapy used to treat many forms of cancers. Prof. Robert Jones (University of Glasgow, Scotland, United Kingdom) discusses the rationale, design, and findings of the randomised phase 2 ATLANTIS trial, of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma. Questions: What is the rationale for the use of cabozantinib in the […]
Neal Shore, AACR 2022: KEYNOTE-992 a Phase 3 Study of Pembrolizumab in Muscle-invasive Bladder Cancer
touchONCOLOGY were delighted to talk with Dr. Neal Shore (GenesisCare; Carolina Urologic Research Center, Myrtle Beach, SC, USA) to discuss the phase 3 study of pembrolizumab plus chemoradiotherapy in the treatment of muscle-invasive bladder cancer. The abstract ‘KEYNOTE-992: A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!